All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 4, 2023
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeks
  • Light bulb shines next to extinguished ones

    Spring cleaning starts early as Sanofi and others cut programs

    It’s the season for reevaluation as companies weed out programs that don’t offer much promise. At the head of the line is Sanofi SA’s once-potential myasthenia gravis blockbuster tolebrutinib. A partial clinical hold on the phase III study is part of the reasoning for stopping its development. But so is competition, the company said. Other companies eliminating development programs include Roche Holding AG, Gilead Sciences Inc., AB Science SA and Merck & Co. Inc.
  • Biopharma financings hit $3.9B in January, down by 22% from last year

  • Today's news in brief

  • Spring cleaning starts early as Sanofi and others cut programs

    It’s the season for reevaluation as companies weed out programs that don’t offer much promise. At the head of the line is Sanofi SA’s once-potential myasthenia gravis blockbuster tolebrutinib. A partial clinical hold on the phase III study is part of the reasoning for stopping its development. But so is competition, the company said. Other companies eliminating development programs include Roche Holding AG, Gilead Sciences Inc., AB Science SA and Merck & Co. Inc.
  • Biopharma financings hit $3.9B in January, down by 22% from last year

    Starting out the year slow, biopharma financings are about 22% below where they were at the end of January last year, and they are well behind the first month of the previous two years as well, suggesting company executives may need to continue to prioritize costly programs as resources are depleted – at least for the near future.
  • Today's news in brief

    BioWorld briefs for Feb. 3, 2023.
  • Myostatin approach gains ground in SMA; Biohaven, Roche, Scholar Rock in mix

    Spinal muscular atrophy (SMA) has been surfacing more regularly in scientific journals lately, as drug developers – such names as Biohaven Inc., Roche Holding AG and Scholar Rock Inc. – continue to search for improved therapies directed at the condition, one that takes in a group of hereditary, motor neuron-destroying diseases.
  • Haya targets lncRNA for tissue-specific fibrosis drugs

    Could long non-coding RNAs be the key to developing organ-specific antifibrotic drugs that only mediate their effects in disease-related contexts? That’s the intriguing hypothesis that Haya Therapeutics SA has set out to explore, and its lead program, in heart failure caused by non-obstructive hypertrophic cardiomyopathy, is now in IND-enabling studies. A first clinical trial is pencilled in for late 2024 or early 2025.
  • Turbine’s cell simulation platform to probe unanswered questions in oncology

    Turbine Ltd. began the new year with a partnership with Cancer Research Horizons, the innovation arm of Cancer Research UK, which will put its Simulatedcell computational biology platform to work on the vexed question of how best to position CDC7 inhibitors in cancer.

BioWorld Insider Podcast

BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness which in many ways goes against the mainstream health care state of mind about obesity.
Listen now

Analysis and data insight

  • Gold wireframe handshake

    Shy of the prior year, deals reach $206B in 2022; M&As fall behind by 36%

    Deals and M&A
    While it made a sturdy effort as biopharma companies opted for licensing deals over M&As in 2022, the year did not surpass 2021 in deal values, falling about 3.5% short. Lackluster M&A values dropped to their lowest levels in five years and were down by 35.6% compared with 2021.
  • Dollar sign, downward arrow

    Biopharma financings stall in 2022; four other years higher than $60.8B raised

    Financings
    The $60.8 billion collected by biopharma companies throughout 2022 is a sharp drop from each of the two prior years, down by 48.6% from 2021 and 54.8% from 2020. Each were standout years by any measure and a direct result of the investment fervor for the industry brought on by the COVID-19...
  • Blue tachometer

    Though down, accelerated approvals not out in 2022

    Regulatory
    In the wake of ongoing criticism over the U.S. FDA’s 2021 accelerated approval of Biogen Inc.’s Alzheimer’s drug, Aduhelm, the percentage of novel drugs receiving accelerated approval last year was the lowest it’s been since 2018.
  • Downward-arrow-on-EU-flag-and-chart.png

    The year of the squeeze: Europe equity funding drops 55% to $6.8B in 2022

    Financings
    For European biotechnology, 2022 was a year of contraction. Disclosed equity investments in European firms engaged in the discovery and development of therapeutics totaled $6.782 billion, down 55% on the previous year’s record-breaking tally of $15.193 billion. Last year’s tally is the worst...
More in Analysis and data insight

Today's news in brief

  • Appointments and advancements for Feb. 3, 2023

  • Financings for Feb. 3, 2023

  • In the clinic for Feb. 3, 2023

  • Other news to note for Feb. 3, 2023

  • Regulatory actions for Feb. 3, 2023

Deals and M&A

  • Kyocera pulls out of Regeneus deal for stem cell therapy Progenza for osteoarthritis

  • CS Pharma gains Chinese rights to Daewoong’s antifibrotic agent, bersiporocin, in $336M deal

  • Sysnav Healthcare, Roche to develop digital endpoints for neuromuscular disease

  • Iovance ‘leukin good after Clinigen transaction as lifileucel BLA stays the course

  • Hutchmed looks beyond China as Takeda gains colorectal cancer asset in $1.13B deal

  • Mabwell out-licenses preclinical iron metabolism MAb to Disc Medicine in $412M deal

  • Neurodegenerative-focused Aprinoia opts for SPAC route in deal valued at $280M

  • Carsgen out-licenses China rights to Huadong for BCMA CAR T for $152M

  • Angion needed help and turns to a merger with Elicio

  • CFIUS singles out mergers with Chinese companies as potential national security threats

Financings

  • The 2022 UK Biotech Financing report: IPOs dropped but venture cap stood strong

    IPO
    It’s been a tough year for raising biotech money, according to the new U.K. Biotech Financing Report, but there are bright spots in an otherwise dark period. What happened last year in the U.K. basically mirrored what happened with global financings as IPOs are significantly down while venture...
  • Grey Wolf raises $49M to advance tumor drug toward phase I/II

    Cancer
  • Cadrenal closes on 2023’s first US IPO

    Cardiovascular
  • Neophore boosts DNA mismatch repair work with series B extension

    Cancer
  • Iaso Bio nets ¥500M as it eyes China nod for CAR T therapy

    Cancer
More in Financings
black cortellis ad

Science

  • Women jogging

    As weight loss medicine advances, its relevance recedes

    Endocrine/Metabolic
    Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. GLP-1R agonists, which are also called incretin mimetics and GLP-1 analogs, are likely to continue...
  • Microsampling plus multiomics enables mail-order metabolism

    Endocrine/Metabolic
    Researchers at Stanford University School of Medicine have developed a method to measure several thousand metabolites, including proteins, metabolites, inflammatory markers such as cytokines and, to a degree, lipids. “It’s like Theranos, except it works,” corresponding author Michael Snyder,...
  • Common network found across multiple psychiatric disorders

    Neurology/Psychiatric
    A psychiatric disorder rarely comes alone. More than half of all individuals who meet the diagnostic criteria for any psychiatric disorder are diagnosed with more than one condition. That high degree of comorbidity is often viewed as a consequence of the heterogeneity of psychiatric disorders – and...
  • UK scientists translating COVID sequencing efforts to monitor respiratory infections

    Infection
  • Targeting prefusion state is better bet for RSV vaccines

    Immune
  • Reindeer and horses and bears, oh my!

  • Senescent cells are toxic to their neighbors, prevent muscle regeneration

    Stem cells
More in Science

Newco news

  • Glucose testing

    Clinical trial on horizon for company that restores the adipocyte

    Diabetes
    After raising an undisclosed sum in a series A round, French biotech company Adipopharma LLC aims to progress its make-or-break targeted insulin resistance peptide into a phase I trial in type 2 diabetes patients by the end of 2023.
  • Traditional Chinese medicine illustration

    ABVC Biopharma on the path to validating traditional medicine for the modern world

    Cancer
    ABVC Biopharma Inc is headquartered in San Francisco but it has its roots in Taiwan where it is digging into traditional medicine and validating it for the modern world. “There are a number of drugs that can’t be synthesized in the lab,” ABVC CEO Howard Doong told BioWorld, so he is going back to...
  • Cross-section of a mouse lung infected with P. aeruginosa and treated with engineered M. pneumoniae

    Pulmobiotics is developing cell therapy for lung diseases, but with a twist

    Cancer
    Pulmobiotics Ltd., which was founded in 2019, is developing cell therapy for lung diseases, including lung cancer. But unlike other cell therapies for cancer, this one is based not on harnessing T cells but on engineering bacteria. The team has engineered Mycoplasma pneumoniae to deliver various...
  • Stem cells

    Juvena looking to hESC-secreted proteins for treating age-related disease

    Musculoskeletal
    Juvena Therapeutics Inc. co-founder and CEO Hanadie Yousef had the company’s name picked out several years before it was officially incorporated in 2017 to combine Yousef’s work in the mechanics of aging with an underutilized class of biologics and an advanced proteomics platform to tackle chronic...
  • Silhouette made of crumpled paper illustrating depression

    Lusaris tackling treatment-resistant depression with neuroplastogen approach

    Neurology/Psychiatric
    Over the past few years, the pandemic clearly has put a spotlight on vaccines and the infectious disease space. But the struggle to adjust in COVID-19’s wake also brought into stark relief another high unmet need. “Coming out of COVID, there was a mental health focus coming into play,” said Andrew...
More in Newco news

Regulatory

  • GSK’s daprodustat cleared as first FDA-approved oral HIF-PHI in CKD-related anemia

  • Decision to expand WTO COVID-19 waiver drags on as pandemic wanes

  • Bcht Biotech gains China’s first approval for domestic zoster vaccine

  • Future of US biosimilar pipeline could rest on Humira competition

  • As geopolitical tensions mount, China increasingly views IP through national security lens

  • US Third Circuit hands biopharma big 340B win

  • Transition period over: EMA’s new clinical trials system in place

  • China’s Alpha Biopharma seeks new drug status for EGFR-TKI product

  • Supplier exec to pay back insider trading gains

  • US FTC asked to oppose biopharma M&As that replace R&D

U.S.

  • Biden administration to allow pandemic-driven public health emergency to end

    Coronavirus
    The Biden administration has determined that the public health emergency (PHE) for the COVID-19 pandemic will not be renewed and thus will come to an end in the second week of May. While the end of the PHE will affect some Medicare telehealth provisions that have not been memorialized in...
  • US GAO report highlights growing use of third-party funding in product liability litigation

    Regulatory
  • Lilly gets accelerated FDA nod for next-gen BTK inhibitor in MCL

    Regulatory
  • VRBPAC backs simplification of COVID-19 vaccines

    Regulatory
  • US FDA seeks simple path forward for COVID-19 vaccines

    Coronavirus
More in U.S.
black cortellis ad

Europe

  • Dupixent

    EMA says yes to Sanofi/Regeneron’s dermatitis drug, no to Ipsen’s bone disease contender

    Regulatory
    Where European regulatory decisions were concerned, there was good news and bad news for pharma today as Sanofi SA and Regeneron Pharmaceuticals Inc. got the go-ahead for expanded approval of Dupixent (dupilumab) in pediatric atopic dermatitis patients whilst Ipsen SA’s ultra-rare bone disease drug...
  • EFPIA: Borders shouldn’t be barriers to EU clinical trials

    Regulatory
    In the absence of a European framework, industry is stepping up with an initiative to help EU patients cross borders to participate in clinical trials.
  • Abbvie, Lilly withdraw from UK pricing scheme over ‘punishing’ 2023 rebate

    Abbvie Inc. and Eli Lilly and Co. Inc. have pulled out of the U.K.’s voluntary pricing scheme for branded drugs in protest at the 26.5% of their revenues they would be required to pay back to the government in 2023.
  • US, Switzerland on path to share GMP inspection findings

    Regulatory
  • New EU stockpile to prepare for CBRN events

  • Biontech teams up with UK for personalized mRNA cancer vaccines

    Clinical
  • EMA moving ahead with clinical trial system despite industry concern

    Clinical
More in Europe

Clinical

  • Trial data on Atrogi’s new diabetes drug imminent

    Diabetes
    By next June or July, Swedish firm Atrogi AB expects to have data from a first-in-human phase Ia/Ib trial of its novel beta-2 adrenergic receptor agonist, ATR-258, which is in development for type 2 diabetes. The study has completed single...
  • Now COVA is over, Biophytis vies for a piece of the COVID-19 pie

    Coronavirus
    Biophytis SA’s investigational treatment for hospitalized COVID-19 patients with severe disease, Sarconeos (BIO-101), reduced the risk of respiratory failure or early death by 44% compared to placebo, final data from a phase II/III COVA trial...
  • Sirnaomics seeks FDA guidance for phase III skin cancer candidate

    Cancer
    Sirnaomics Ltd. is gearing up to start a phase III clinical trial for its lead siRNA candidate, STP-705, for the treatment of two non-melanoma skin cancers: squamous cell carcinoma in situ and basal cell carcinoma. STP-705 comprises two siRNA...
  • Taysha ponders new study for ultra-rare disease as stock droops

    Neurology/Psychiatric

    Taysha Gene Therapies Inc.’s stock (NASDAQ:TSHA) struggled Feb. 1 following the U.S. FDA’s recommendation that the company dose more patients in a double-blind, placebo-controlled study of TSHA-120 for the ultra-rare indication giant axonal...

  • Evelo’s path in AD not EASI as placebo response garbles SINTAX of phase II effort

    Dermatologic
    Evelo Biosciences Inc.’s late-stage efforts with EDP-1815 are forging ahead despite unfavorable data in atopic dermatitis (AD), and talks so far with the U.S. FDA have proven encouraging, the company said. Cambridge, Mass.-based Evelo made public...
  • Sciwind Biosciences starts patient dosing in phase III clinical trial for ecnoglutide

    Diabetes
    Sciwind Biosciences Co. Ltd. started dosing in a phase III clinical trial in China of its ecnoglutide (XW-003) candidate in adults with type 2 diabetes, targeting patients who have not responded adequately to either metformin or changes in lifestyle.
More in Clinical

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • Rethinking obesity: Fitness may be more directly linked to health than weight
  • Looking ahead to 2023: CEOs contemplate the new normal
  • Psychedelic evolution: Mindset Pharma looks to change mental health treatment
  • $1B+ biopharma deals keep values afloat, even amid muted volume
  • Extending the human lifespan
  • New therapies vie to change fatal course of amyotrophic lateral sclerosis
  • Biopharma’s correction? 2022 1Q investments are both up and down
  • Who advises the CDC on big COVID decisions and how’s that working out?
  • Long COVID: Potentially the next public health crisis
  • What happens when your inventor is an artificial intelligence?

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing